婴儿期发病的腓骨肌萎缩症家系PMP22基因突变研究

邢军卫; 刘亚红; Bilal Haider SHAMSI; 刘小红; 谭璐; 徐曼

PDF(1262 KB)

中国当代儿科杂志 ›› 2011, Vol. 13 ›› Issue (10) : 799-803.

论著·临床研究

婴儿期发病的腓骨肌萎缩症家系PMP22基因突变研究

邢军卫，刘亚红，Bilal Haider SHAMSI，刘小红，谭璐，徐曼

作者信息 +

PMP22 mutation of an infant-onset Charcot-Marie-Tooth disease family

XING Jun-Wei, LIU Ya-Hong, Bilal Haider SHAMSI, LIU Xiao-Hong, TAN Lu, XU Man

Author information +

文章历史 +

摘要

目的：研究一个婴儿期发病的腓骨肌萎缩症（CMT）家系PMP22基因突变，探讨该家系CMT的遗传学特点。方法：应用STR结合多重PCR法对2例CMT患儿及该家系内15名表型正常的成员进行PMP22基因重复突变的分析。同时选择20名健康人做为对照。结果：在2名CMT患儿及5名家系内表型正常的成员中发现了PMP22基因重复突变，其中5例突变在STR位点D17S921，2例突变在STR位点D17S4A，而家系内其余10名成员及20名健康人未发现突变。结论：该CMT家系的致病基因为17p11.2-p12区域内包含PMP22基因的重复突变，其亚型为CMT1A。

Abstract

OBJECTIVE: To study the mutation of PMP22 gene of an early-onset family with Charcot-Marie-Tooth disease (CMT) and the genetic features of the disease. METHODS: Two patients with CMT, fifteen unaffected members in the family and 20 healthy controls were enrolled. STR-PCR and gene scanning were used to detect PMP22 duplication mutation. RESULTS: The mutations of PMP22 were found in the two patients and other five unaffected members in the family. The mutations were located in the STR locus D17S921 in 5 cases and in the STR locus D17S4A in 2 cases. The other members in the family and 20 healthy controls did not show the mutations of PMP22. CONCLUSIONS: The gene causing CMT in the family is found in the 17p11.2-p12 region containing PMP22 gene duplication mutation, resulting in the subtype CMT1A.

导出引用

邢军卫，刘亚红，Bilal Haider SHAMSI，刘小红，谭璐，徐曼. 婴儿期发病的腓骨肌萎缩症家系PMP22基因突变研究[J]. 中国当代儿科杂志. 2011, 13(10): 799-803

XING Jun-Wei, LIU Ya-Hong, Bilal Haider SHAMSI, LIU Xiao-Hong, TAN Lu, XU Man. PMP22 mutation of an infant-onset Charcot-Marie-Tooth disease family[J]. Chinese Journal of Contemporary Pediatrics. 2011, 13(10): 799-803

中图分类号： R596

参考文献

［1］Howcroft DWJ, Umar SK, Makwana N. Charcot Marie Tooth disease［J］. Orthop Trauma, 2009,23(4): 274-277.

［2］吴江. 神经病学［M］ // 贾建平, 崔丽英. 北京: 人民卫生出版社, 2005: 322-325.

［3］Choi BO, Lee MS, Shin SH, Hwang JH, Choi KG, Kim WK, et al. Mutational analysis of PMP22,MPZ,GJB1,EGR2 and NEFL in Korean Charcot-Marie-Tooth neuropathy patients［J］. Human Mutat, 2004, 24(2):185-186.

［4］Padua L, Shy ME, Aprile I, Cavallaro T, Pareyson D, Quattrone A, et al. Correlation between clinical/neurophysiological findings and quality of life in Charcot-Marie-Tooth type 1A［J］. J Peripher Nerv Syst, 2008, 13(1):64-70.

［5］Padua L, Aprile I, Cavallaro T, Commodari I, La Torre G, Pareyson D, et al. Variables influencing quality of life and disability in Charcot Marie Tooth(CMT) patients: Italian multicentre study［J］. Neurol Sci, 2006, 27(6):417-423.

［6］Pareyson D. Differential diagnosis of Charcot-Marie-Tooth disease and related neuropathies［J］. Neurol Sci, 2004, 25(2):72-82.

［7］Szigeti K, Nelis E, Lupski JR. Molecular diagnostics of Charcot-Marie-Tooth disease and related peripheral neuropathies［J］. Neuromolecular Med, 2006, 8(1-2):243-254.

［8］Carter GT, England JD, Chance PF. Charcot-Marie-Tooth disease:electrophysiology, molecular genetics and clinical management［J］. IDrugs, 2004, 7（2）:151-159.

［9］Corrado G, Checcarelli N, Santarone M, Stollberger C, Finsterer J. Left ventricular hypertrabeculation/noncompation with PMP22 duplication-based Charcot-Marie-Tooth type 1A［J］. Cardiology, 2006, 105(3):142-145.

［10］Passage E, Norreel JC, Noack-Fraissignes P, Sanguedolce V, Pizant J, Thirion X, et al. Ascorbic acid treatment corrects the phenotype of a mouse model of Charcot-MarieTooth disease［J］. Nat Med, 2004, 10(4):396-401.

［11］Kaya F, Belin S, Bourgeois P, Micaleff J, Blin O, Fontes M. Ascorbic acid inhibits PMP22 expression by reducing cAMP levels［J］. Neuromuscul Disord, 2007, 17(3):248-253.

［12］Verhamme C, de Haan RJ, Vermeulen M, Baas F, de Visser M, van Schaik IN. Oral high dose ascorbic acid treatment for one year in young CMT1A patients: a randomised, double-blind, placebo-controlled phase II trial［J］. BMC Med, 2009, 7:70.

［13］Sereda MW, Nave KA. Animal models of Charco-Marie-Tooth disease type 1A［J］. Neuromolecul Med, 2006, 8(1-2):205-216.

［14］Reillya MM, Shyb ME, Muntonic F, Pareysonet D. 168th ENMC International Workshop: outcome measures and clinical trials in Charcot-Marie-Tooth disease (CMT)［J］. Neuromuscul Disord, 2010, 20(12):839-846.

［15］Pareyson D, Reilly MM, Schenone A, Fabrizi GM, Cavallaro T, Santoro L, et al. Ascorbic acid in Charcot-Marie-Tooth disease type 1A (CMT-TRIAAL and CMT-TRAUK): a doubleblind randomised trial［J］. Lancet Neurol, 2011, 10(4):320-328.